OncoMatch/Clinical Trials/NCT06530511
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Is NCT06530511 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Polatuzumab vedotin and Rituximab for diffuse large b cell lymphoma.
Treatment: Polatuzumab vedotin · Rituximab · Orelabrutinib — This prospective, single-arm, multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL. This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab, Rituximab, and orelabrutinib in this population. The primary endpoint is CR rate after induction therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC < 1.5 x 10^9/L, PLT < 80 x 10^9/L, INR > 1.5 x ULN, PT and APTT > 1.5 x ULN (unless caused by Lymphoma)
Kidney function
Creatinine high 1.5 times the upper limit of normal, Creatinine clearance < 60 mL/min (unless caused by Lymphoma)
Liver function
ALT or AST 2 times higher than upper limit of normal, AKP and Bilirubin 1.5 times higher than upper limit of normal (unless caused by Lymphoma)
Laboratory abnormalities at screening (unless caused by Lymphoma) A) ANC < 1.5 x 10^9/L, PLT < 80 x 10^9/L b） Coagulation: INR greater than 1.5 x upper limit of normal; PT and APTT greater than 1.5 x upper limit of normal c） Liver function: ALT or AST 2 times higher than upper limit of normal, AKP and Bilirubin 1.5 times higher than upper limit of normal d） Renal function: Creatinine high 1.5 times the upper limit of normal, Creatinine clearance < 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06530511 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify